Three Peptides, Three Very Different Verdicts on Fat Loss

The short version

Smart Choice Peptides is a reading room, not a shop. It exists to answer one question honestly for each of three peptides commonly grouped under the banner of weight management: what did the actual human research find, and how far does that evidence really reach?

A peptide is a short chain of amino acids — the same building blocks that make up proteins, just far smaller. Each compound here is built to imitate or amplify a hormone the body already makes. AOD-9604 mimics a fragment of growth hormone once thought to drive fat metabolism on its own. Tesamorelin amplifies the natural signal that tells the pituitary gland to release growth hormone. Tirzepatide mimics two separate gut hormones that jointly regulate appetite and blood sugar.

One of these three failed its pivotal human trial. One is FDA-approved for a narrow, specific use. One is FDA-approved broadly and currently sets the pace for weight loss in its drug class. This site reports all three outcomes plainly, cites every figure, and recommends no dose for anyone.

Weight-management research peptides, compared

The three peptides on this desk are grouped by purpose — each has been investigated, in one way or another, for its effect on body fat or metabolic regulation — not by mechanism, and the mechanisms could hardly be more different.

AOD-9604 is a fragment of human growth hormone, isolated specifically because researchers wanted the fat-burning piece of GH without the growth-promoting, blood-sugar-raising piece. It worked cleanly in rodents ^[4][5] and looked safe in roughly 900 human subjects ^[3] — but it did not produce statistically significant weight loss against placebo in its pivotal human program, and the obesity development effort was shelved.

Tesamorelin takes an upstream approach: rather than supplying a growth-hormone fragment directly, it stimulates the pituitary gland to release more of the body's own growth hormone. That approach has real trial numbers behind it — a meta-analysis of five randomized trials found consistent reductions in visceral fat and liver fat ^[6] — but its FDA approval covers one specific population, not general weight management.

Tirzepatide is the outlier by scale: a dual-receptor incretin mimetic that beat semaglutide, a leading single-receptor competitor, by roughly 6.5 percentage points of body weight in a head-to-head trial ^[11]. It is also the most heavily studied and most side-effect-documented compound of the three.

Reading them side by side is less about picking a winner and more about calibrating expectations against what was actually tested.

What are research peptides?

All three compounds on this desk are described in the literature as research peptides or investigational compounds at some point in their development, though they've landed in different places. Tesamorelin and tirzepatide are now FDA-approved prescription medicines with defined indications, dosing, and manufacturing standards. AOD-9604 never reached approval anywhere; its obesity program was discontinued after the pivotal trial missed its primary endpoint, and any material sold today as 'research-grade AOD-9604' falls outside any approved-product quality or safety oversight.

That distinction matters more than the marketing around these compounds usually suggests. 'Research peptide' is sometimes used as a label to sidestep prescribing rules, not as a statement about scientific maturity. This site treats the label literally: a compound is investigational until a regulator says otherwise, and even an approved medicine is only approved for what it was actually studied for. Nothing here is written as, or should be read as, an instruction to obtain, combine, or self-administer any of these compounds.

How this desk reads the evidence

Each compound page here follows the same discipline: a plain-English summary first, then what the molecule is and how it works, then the actual clinical or preclinical trial results with citations, then what people report using it (clearly labeled as anecdotal), then the safety cautions the literature actually supports. A single references list aggregates every source cited across all three pages and the comparison page.

Where a trial failed to show a benefit — as with AOD-9604's human obesity program — this desk says so as plainly as it reports a win. Where an approval is narrow — as with tesamorelin's HIV-lipodystrophy indication — the scope of that approval is stated, not implied to be broader. Where evidence is strong and current, as with tirzepatide's head-to-head trial data, that strength is also stated plainly. The goal throughout is calibration, not persuasion.